Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 22;7(1):2.
doi: 10.3390/vaccines7010002.

Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate

Affiliations

Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate

Eranga Abeyratne et al. Vaccines (Basel). .

Abstract

Our previous investigation of the nucleolar localisation sequence (NoLS) of chikungunya virus (CHIKV) capsid protein demonstrated the role of capsid in CHIKV virulence. Mutating the NoLS of capsid in CHIKV led to the development of a unique live-attenuated CHIKV vaccine candidate, termed CHIKV-NoLS. CHIKV-NoLS-immunised mice developed long-term immunity from CHIKV infection after a single dose. To further evaluate CHIKV-NoLS attenuation and suitability as a vaccine, we examined the footpad of inoculated mice for underlying CHIKV-NoLS-induced immunopathology by histological and flow cytometric analysis. In comparison to CHIKV-WT-infected mice, CHIKV-NoLS-inoculated mice exhibited minimal inflammation and tissue damage. To examine the stability of attenuation, the plaque phenotype and replication kinetics of CHIKV-NoLS were determined following extended in vitro passage. The average plaque size of CHIKV-NoLS remained notably smaller than CHIKV-WT after extended passage and attenuated replication was maintained. To examine thermostability, CHIKV-NoLS was stored at 21 °C, 4 °C, -20 °C and -80 °C and infectious CHIKV-NoLS quantified up to 84 days. The infectious titre of CHIKV-NoLS remains stable after 56 days when stored at either -20 °C or -80 °C. Interestingly, unlike CHIKV-WT, the infectious titre of CHIKV-NoLS is not sensitive to freeze thaw cycles. These data further demonstrate preclinical safety and stability of CHIKV-NoLS.

Keywords: alphavirus; chikungunya virus; live-attenuated; preclinical; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Figures

Figure 1
Figure 1
Histological analysis of the mouse footpad after inoculation with 104 plaque forming units (PFU) CHIKV-WT or CHIKV-NoLS. Twenty-eight-day-old C57BL/6 mice were inoculated in the ventral/lateral side of the right foot with 104 PFU CHIKV-WT or CHIKV-NoLS or mock-infected with (phosphate buffered saline) PBS alone. (a) CHIKV-induced footpad swelling was assessed daily by measuring the height and width of the perimetatarsal area of the hind foot. Each symbol represents the mean ± standard error from 5 mice; (b) Inoculated (ipsilateral) feet were dissected, processed for histological analysis and stained with H&E. Images at 100× and 200× magnification are representative of at least 6 fields of view. Black arrows indicate cellular infiltration. The black dashed box indicates the area magnified at 200×. The size bars represent 100 µm; (c) Cellular infiltrates at 200× magnification were quantified using ImageJ software. ***, p < 0.001, ns―not significant. Statistical analyses were performed using one-way ANOVA with Tukey’s post-test. Data represents the mean ± standard error.
Figure 2
Figure 2
Cellular infiltrates in the feet of inoculated mice were analysed using flow cytometry. (a) Total live CD45+ leukocytes, (b) CD4+ and CD8+ T cells (CD3+), (c) inflammatory monocytes (Ly6Chi Ly6G- CD11bhi MHC-II+), (d) Neutrophils (Ly6Ghi CD11bhi) and (e) tissue macrophages (Ly6Clo CD11bhi Ly6G- MHC-II+). *, p < 0.05, **, p < 0.01, and ****, p < 0.0001. Statistical analyses were performed using a Mann–Whitney U-test (A, B, C, D) or a a two-way ANOVA with a Holm-Sidak comparison correction. Data represents the mean ± standard error.
Figure 3
Figure 3
Multistep growth kinetics of CHIKV-NoLS in C6/36 cells after extended in vitro passage. C6/36 cells were infected with CHIKV-WT, P0 CHIKV-NoLS or P5 CHIKV-NoLS at an MOI of 0.1 PFU/cell. Supernatants were collected at the indicated time points, and infectious virus was quantified by plaque assay. **, p < 0.01, and ***, p < 0.001. Statistical analyses were performed using two-way ANOVA with Bonferroni post-tests. Each symbol represents the mean ± standard error from 3 independent experiments.
Figure 4
Figure 4
CHIKV-NoLS plaque size after extended in vitro passage. CHIKV-NoLS and CHIKV-WT were passaged 10 times in Vero cells at 37 °C using a multiplicity of infection of 0.1 PFU/cell. With each passage of virus, Vero cells were infected with 30 PFU and plaque size measured using ImageJ software. Each dot represents one plaque. Dashed lines represent the mean plaque size for CHIKV-NoLS and CHIKV-WT at passage 0.
Figure 5
Figure 5
Long term thermostability of CHIKV-NoLS. CHIKV-NoLS and CHIKV-WT were diluted to 5 × 105 pfu/ml and vials stored at 21 °C, 4 °C, −20 °C and −80 °C. At the indicated time points infectious CHIKV-NoLS and CHIKV-WT was quantified by plaque assay. Each symbol represents the mean ± standard error.
Figure 6
Figure 6
Stability of CHIKV-NoLS infectivity following repeated freeze thaw cycles. CHIKV-NoLS and CHIKV-WT were diluted to 5 × 105 PFU/mL and vials stored at −80 °C. Vials were thawed on ice and infectious CHIKV-NoLS and CHIKV-WT quantified by plaque assay. Vials were returned to −80 °C and the process repeated. Each symbol represents the mean ± standard error.

References

    1. Silva L.A., Dermody T.S. Chikungunya virus: Epidemiology, replication, disease mechanisms, and prospective intervention strategies. J. Clin. Invest. 2017;127:737–749. doi: 10.1172/JCI84417. - DOI - PMC - PubMed
    1. Powers A.M. How chikungunya virus virology affects its epidemiology and transmission: Implications for influencing public health. J. Infect. Dis. 2016;214:4494. doi: 10.1093/infdis/jiw382. - DOI - PubMed
    1. Queyriaux B., Simon F., Grandadam M., Michel R., Tolou H., Boutin J.P. Clinical burden of chikungunya virus infection. Lancet Infect. Dis. 2008;8:2–3. doi: 10.1016/S1473-3099(07)70294-3. - DOI - PubMed
    1. Sissoko D., Malvy D., Ezzedine K., Renault P., Moscetti F., Ledrans M., Pierre V. Post-epidemic chikungunya disease on reunion island: Course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl. Trop. Dis. 2009;3:e389. doi: 10.1371/journal.pntd.0000389. - DOI - PMC - PubMed
    1. Lemant J., Boisson V., Winer A., Thibault L., Andre H., Tixier F., Lemercier M., Antok E., Cresta M.P., Grivard P., et al. Serious acute chikungunya virus infection requiring intensive care during the reunion island outbreak in 2005-2006. Crit. Care Med. 2008;36:2536–2541. doi: 10.1097/CCM.0b013e318183f2d2. - DOI - PubMed

LinkOut - more resources